With vasa-Cas9, high efficiency and self-limiting suppression was achieved. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

To tackle a backlog in toxicity testing, US federal scientists are modernizing programs with high-throughput assays and AI.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Distant metastasis is the major cause of ...